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GLUCOSE AND COGNITIVE DYSFUNCTION
Abstract
Growing evidence suggests that impaired glucose tolerance may contribute to the development
of cognitive dysfunction in otherwise healthy individuals (Neergard et al., 2017). The goal of this
study was to clarify the relationship between pre-clinical insulin resistance, as estimated by
plasma glucose levels, and cognitive functioning in older adults. It was hypothesized that glucose
levels at the higher end of the normal range are associated with cognitive dysfunction and with
differences in brain activation during a working memory task. Participants completed the Brief
Cognitive Rating Scale (BCRS; Reisberg et al., 1988), Global Deterioration Scale (GDS;
Reisberg et al., 1982), Mattis Dementia Rating Scale (MDRS; Mattis, 1988), Repeatable Battery
for the Assessment of Neuropsychological Status (RBANS; Randolph et al., 1988), Letter
Number Sequencing Test (LNS; Wechsler, 2008), Cognitive Change Index (CCI; Saykin et al.,
2006), Symbol Digit Modalities Test (SDMT; Forn et al., 2013), and the Delis-Kaplan Executive
Function System (D-KEFS; Delis et al., 2001). A series of correlations between fasting glucose
levels and cognitive test performance was computed. Fasting glucose levels were positively
associated with BCRS and GDS scores but no other measures. In addition, an independent
samples t-test comparing cognitive performance of the high glucose group (glucose ≥ 100
mg/dL) and low glucose group (glucose < 100 mg/dL) indicated performance differences in
executive functioning and verbal fluency. BMI was an additional factor associated with cognitive
dysfunction. This study and future studies with larger sample sizes may help to inform new
blood glucose control guidelines in healthcare, as even the higher end of the normal blood
glucose range may be associated with cognitive decline.
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Introduction
The neurodegenerative conditions seen in aging populations represent a substantial social
and economic burden on society. In light of the growing aging population, these age-related
neurodegenerative disorders are expected to become more prevalent and are thus of increasing
public concern (Zahra et al., 2020). Neurodegenerative disorders are characterized by a
progressive reduction in most cognitive functions, which negatively affect a person’s behavior,
personality, social relationships, and can make it difficult to function in daily life (Dugger &
Dickson, 2017). The development of these cognitive disorders, the most common being
Alzheimer’s disease, is thought to begin years or even decades prior to the clinical diagnosis of
the disorder. Because diagnosis of these neurodegenerative conditions tends to occur late in the
disease process, it is important to identify and address potential risk factors that may contribute
to the development of cognitive dysfunction (Tarawneh & Holtzman, 2012).
One potentially modifiable risk factor that has been implicated in the development of
cognitive dysfunction is insulin resistance. Insulin is a hormone that maintains glucose
homeostasis in the periphery, but that also has numerous important functions in the brain
(Cholerton et al., 2013). Disruption in insulin signaling commonly occurs in Type 2 diabetes,
which is a disease that is characterized by insulin resistance. Insulin resistance is defined as the
reduced sensitivity of cells to the effects of insulin and has been shown to be a risk factor for
cognitive dysfunction (Ma et al., 2015). In light of the high prevalence of insulin resistanceassociated conditions and their potential link to cognitive dysfunction, blood sugar control may
be an important target for the prevention of cognitive decline (Meigs, 2003). Recent studies have
indicated that even pre-clinical insulin resistance and impaired glucose tolerance may be
associated with the early stages of cognitive decline (Laws et al., 2017). This study looked at the
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effects of impaired glucose tolerance, as measured by fasting blood glucose levels, and cognitive
performance in a sample of older adults.
Insulin is a peptide that is secreted by pancreatic beta cells to maintain glucose
homeostasis. Maintaining optimal plasma glucose levels is critical to ensure that there is
sufficient energy available for cellular metabolic processes. Insulin controls blood glucose
concentrations by stimulating glucose transport into adipose and muscle tissue. Insulin also
lowers blood glucose concentrations by inhibiting hepatic glucose production. More specifically,
insulin molecules bind to cellular insulin receptors, which leads to a cascade of cellular events
that in turn signal insulin-sensitive glucose transporters inside the cell to move to the membrane
of insulin-sensitive peripheral tissue (Saltiel & Kahn, 2001). The activated glucose transporter
promotes the use of glucose in the cells. Controlling glucose uptake becomes particularly
important in the period following the ingestion of food, called the postprandial state. In the
postprandial state insulin levels rise in order to promote the transport of glucose into the cells and
lower blood glucose levels (Lefèbvre & Scheen, 1999).
Historically, insulin signaling was thought to be restricted to the periphery where it
regulates glucose levels. The view that the brain is an insulin-insensitive organ was primarily
informed by studies that found that glucose transport through the blood-brain barrier into the
brain was not affected by insulin levels in the periphery. For example, Hasselbach et al. (1999)
found that peripheral insulin concentrations were not correlated with blood-brain barrier glucose
transport or net cerebral glucose metabolism in humans (Hasselbach et al., 1999). However, it is
now known that there are two potential routes that allow peripheral insulin to reach the brain.
Peripheral insulin can cross the blood-brain barrier through brain microvascular endothelial cell
uptake (Banks et al., 2014; Gray et al., 2014). It can also flow directly into the cerebrospinal
5
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fluid without having to cross the blood-brain barrier, because there are circumventricular regions
that have porous capillaries instead of the typical blood-brain barrier (Gray et al., 2014). While
the exact mechanisms and relative contributions of these two routes are unknown, it is thought
that insulin that is actively transported through brain endothelial cells then mixes with insulin in
the cerebrospinal fluid and eventually enters brain interstitial fluid (Gray et al., 2014). This
theory is supported by studies that have found that peripheral insulin levels are correlated with
the insulin levels found in cerebrospinal fluid (Levin et al., 2011). This provides evidence that
peripheral insulin can cross the blood-brain barrier and reach brain tissue even though it does not
significantly affect cerebral glucose metabolism.
Research over the past decade has shown that insulin has numerous effects in the CNS
that are largely unrelated to the metabolic functions of insulin (Pomytkin et al., 2018). More
specifically, insulin affects the areas in the brain involved in global cognitive and memory
functions. It is an important regulator of synapse formation and synaptic plasticity in the
hippocampus and in other brain regions involved in learning and memory (Baskin et al., 1987;
Chiu & Cline, 2010; Levin & Sherwin, 2011). It also modulates the release of the
neurotransmitters acetylcholine and norepinephrine, which both play a role in cognition
(Cholerton et al., 2013). Insulin is also thought to serve as a neuroprotective agent. Studies have
shown that it has antiapoptotic effects and that it can protect against beta amyloid toxicity,
oxidative stress, and ischemia (Blazquez et al., 2014).
Due to the important role of insulin in these various cognitive functions, it is no surprise
that disruptions in insulin signaling are associated with a higher risk for cognitive impairment
and dementia compared to healthy controls with normal insulin signaling (Whitmer et al., 2008).
Disruption in insulin signaling commonly occurs in Type 2 diabetes, which is a disease that is
6
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characterized by insulin resistance. In insulin resistance, prolonged peripheral hyperinsulinemia
causes insulin receptors to down regulate, rendering tissue unresponsive to insulin (Cholerton et
al., 2013). Impairments in insulin signaling have been linked to the development of brain
pathologies like Alzheimer’s disease (Laws et al., 2017). The development of these cognitive
dysfunctions in individuals with insulin resistance is thought to be triggered by hyperglycemic
toxicity, chronic inflammatory processes, and mitochondrial dysfunction (Lee et al., 2016).
Individuals with Alzheimer’s disease have also been shown to have a reduction in neuronal
insulin receptors, demonstrating that the desensitization of neuronal insulin receptors is related to
Alzheimer’s disease pathology (Hoyer, 2002; Cholerton et al., 2013). Another line of evidence
for the role of insulin resistance in Alzheimer’s pathology comes from studies that showed that
insulin resistance disrupts amyloid beta plaque (Aβ) clearance and degradation (Ho et al., 2004).
Aβ plaques are found in high concentrations in the brains of individuals with Alzheimer’s
disease and are thought to interfere with normal neuronal communication (Cholerton et al.,
2013). Together, these findings suggest that insulin resistance may precipitate the pathological
symptoms of Alzheimer’s disease.
Moreover, studies have looked specifically at the relationship between insulin resistance
and cognition in patients with Alzheimer’s disease, with findings suggesting that an increase in
insulin resistance is significantly associated with the clinical stages of Alzheimer’s disease. The
Australian Imaging, Biomarkers and Lifestyle (AIBL) Study of Aging investigated the
relationship between insulin resistance and cognitive performance across several domains in
cognitively normal patients and in patients with Alzheimer’s disease. This study found that
measures of insulin resistance were significantly higher in patients with Alzheimer’s disease
compared to cognitively normal patients. These findings indicate that insulin resistance may
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contribute to the cognitive dysfunction seen in Alzheimer’s disease. Furthermore, higher
measures of insulin resistance were associated with poorer performance on cognitive measures in
patients with Alzheimer’s disease. Interestingly, even in cognitively normal individuals,
increases in insulin resistance were still associated with reductions in global cognition (Laws et
al., 2017). Findings from the Prospective Epidemiological Risk Factor Study (n = 2,103), a
prospective study of older women in Denmark, suggested that subjects with impaired fasting
plasma glucose and insulin resistance also have a higher probability of developing cognitive
dysfunction. Fasting plasma glucose level was the single metabolic risk factor that was most
strongly associated with cognitive dysfunction, with subjects having a 44% higher likelihood of
cognitive dysfunction compared to normoglycemic subjects (Neergaard et al., 2017).
Given that Alzheimer’s disease and Type 2 diabetes are both characterized by long
prodromal periods, it is difficult to study the progressive relationship between the two (Laws,
2017). Thus, the association between the pre-clinical stages of diabetes and cognitive function in
non-demented adults is less clear and remains understudied. One study looking at the disease
progression of dementia found that the presence of pre-diabetes accelerated the cognitive decline
in dementia patients (Xu, 2010). Another study had similar findings, indicating that features of
insulin resistance were associated with Alzheimer’s disease (Kuusisto et al., 1997). Other studies
have indicated that impaired glucose tolerance even without diabetes is associated with impaired
verbal fluency and memory (Kanaya et al., 2004; Vanhanen et al., 1998). However, more
research is needed to examine this association between pre-clinical insulin resistance and
cognitive dysfunction in non-demented adults.
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In addition to Type 2 diabetes and Alzheimer’s disease, changes in insulin signaling are
also seen in normal aging processes. In fact, even in the absence of a major risk factor like
obesity, older adults are at an increased risk of developing insulin resistance (Muller et al.,
1996). High fasting blood glucose and insulin resistance can contribute to the progression of
neurodegenerative diseases commonly seen in aging individuals. It is particularly important for
older adults to identify and address potential risk factors like insulin resistance because
modifying these factors at the earliest stage is critical for effective prevention of later cognitive
decline. In light of the growing aging population, older individuals without diabetes but who are
starting to show signs of insulin resistance likely represent a large population at additional risk
for cognitive dysfunction, which have significant societal and economic impacts (Cowie et al.,
2006).

The studies above outline the changes in cognition that can occur in individuals with
insulin resistance and impaired glucose tolerance. However, there has been conflicting evidence
regarding which specific cognitive domains are most affected by elevated blood sugar and other
measures of insulin resistance. Laws et al. (2017) found that greater insulin resistance was
associated with poorer performance on measures of episodic memory, executive function, and
global cognition (Laws et al., 2017). Conversely, another study found that insulin resistance was
only associated with deficits in verbal fluency (Benedict et al., 2012). The functional areas of the
brain that are linked to verbal fluency performance are the frontal and temporal lobes, which are
involved in memory processes. Reductions in memory functions (episodic memory, verbal
memory, working memory, and visual retention), executive functioning, and psychomotor speed
have been most consistently observed in individuals with Type 2 diabetes, making it likely that
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those cognitive domains are also affected in the preclinical stages of diabetes (Palta et al., 2014;
Kodl & Seaquist, 2008).

The findings of some studies have indicated that the cognitive profile associated with
insulin resistance may be similar to that seen in normal aging processes, which affects areas such
as processing speed, executive functioning, and attention (Salthouse, 1996; Craik et al., 2010).
For instance, Yeung et al. (2009) found that healthy controls performed better than patients with
Type 2 diabetes only on measures of executive functioning and processing speed (Yeung et al.,
2009). These findings suggest that Type 2 diabetes may be associated with exacerbating the
neurodegenerative processes seen in aging (Enzinger et al., 2005). However, it is also worth
noting that not all studies have found an association between impaired glucose tolerance or Type
2 diabetes and cognitive performance (Scott et al., 1998; Kodl & Seaquist, 2008). More research
is needed to further understand if and which cognitive domains are affected by pre-clinical
insulin resistance.

The mixed results in the association between impaired glucose tolerance, insulin
resistance and cognitive measures are also reflected in functional magnetic resonance (fMRI)
studies looking at the effects of insulin resistance on brain functioning. Insulin resistance is
thought to affect specific brain regions, primarily the hippocampus, the prefrontal cortex, and the
cingulate gyrus. It is thought that a loss of functional connectivity of the default mode network in
these regions may help to explain the cognitive dysfunction seen in type 2 diabetes, insulin
resistance, and dementia (Kullmann et al., 2012). The default mode network refers to the
baseline cognitive state of a subject that is active when one is awake but not involved in any
specific mental task (Moheet et al., 2015). This network also involves brain regions that are
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involved in attention and executive functioning. Interestingly, Alzheimer’s disease and Type 2
diabetes have both been observed to have decreased functional connectivity of the posterior
cingulate cortex in the default mode network (Musen et al., 2012; Greicius et al., 2003). High
blood glucose has also been associated with impaired deactivation of the default mode network,
indicating that impaired glucose tolerance may contribute to cognitive dysfunction (Marder et al.,
2014).

In addition to alterations of the default mode network, fMRI studies have also indicated
alterations in neural network activity during memory tasks in patients with Type 2 diabetes
(Wood et al., 2016). For instance, Wood et al. (2016) found that the insulin resistance seen in
Type 2 diabetes is associated with reduced activation in left hemisphere temporoparietal regions
and greater activation in bilateral posteriorly distributed regions during a memory task, providing
evidence that Type 2 diabetes is associated with memory related neuronal dysfunction (Wood et
al., 2016). Other studies have found that patients with Type 2 diabetes exhibit hyperactivation of
working memory-related brain circuits, which can be interpreted as being a compensatory brain
activation due to brain inefficiency related to hyperglycemia (He et al., 2015).

Obesity is another factor that has been associated with both insulin resistance and
cognitive dysfunction (Kahn & Flier, 2000; Qizilbash et al., 2015). Obesity is known to almost
double the risk of Alzheimer’s disease development and thus serves as an additional risk factor
for cognitive dysfunction (Anstey et al., 2011). The most common way to assess if a patient is
overweight or obese is to determine their body mass index (BMI), which is the weight of an
individual in kilograms divided by the square of his or her height in meters. BMI has been
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correlated with the development of Alzheimer’s disease and other dementias, particularly in
subjects with insulin resistance and Type 2 diabetes (Benito-Leon et al., 2013).

Because the interplay between aging, obesity, elevated fasting blood glucose levels,
insulin resistance and cognitive dysfunction is complex it is often grouped together under the
term “metabolic syndrome.” Metabolic syndrome is defined as a collection of risk factors that
increase your chance of developing heart disease, diabetes, stroke, and dementia (Saklayen,
2018). Even though there are many factors involved in this syndrome, prior research has shown
that a decrease in insulin sensitivity in the central nervous system may represent a potential link
between metabolic and cognitive dysfunction (Laws et al., 2017).

In sum, while it is well understood that Type 2 diabetes is a risk factor for dementia,
more recent findings suggest that even non-clinically impaired individuals who are showing
signs of insulin resistance and impaired glucose tolerance may also be at risk of cognitive
dysfunction. Furthermore, reductions in cognition in individuals with elevated markers of insulin
resistance have been identified in a handful of studies, but there has been conflicting evidence
regarding which cognitive domains are most vulnerable to the effects of early blood glucose
dysregulation and insulin resistance (Laws et al., 2017; Benedict et al., 2012; Palta et al., 2014).
Lastly, most research linking blood glucose dysregulation and cognitive dysfunction has not
been focused solely on older adults who may represent an at-risk population. Therefore, this
study hoped to build on existing evidence to understand the impact of fasting blood sugar on
cognitive function in individuals whose blood glucose levels are still in the normal range, but
who we propose are at risk for cognitive dysfunction. This study had three hypotheses: 1) plasma
glucose levels at the higher end of the normal range are negatively associated with cognitive
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performance, 2) early cognitive processing stages are most affected in pre-clinical insulin
resistance in a population of older adults, and 3) higher plasma glucose levels are associated with
compensatory changes in brain activation during an fMRI working memory task.

Methods
Participants
Participants were 22 healthy, non-diabetic, non-obese adults, aged 50-75 years, M(SD)=
65.91(6.07). Of these participants, 16 were female and 6 were male. The mean level of education
as measured by years of schooling was 16.39 years (SD=1.78) (see Table 1 for demographic
information). Participants were recruited into two ongoing studies in the Dumas lab: One study
focuses on the effects of fatty acids on brain functioning in older adults (DIET study) and the
other study focuses on cognition after menopause and risk factors related to Alzheimer’s disease
(CHAMP study). In both studies, all participants completed cognitive and behavioral screenings
at baseline, which are described in the following section.
Measures
This study included measures of physical health, cognitive and behavioral performance,
neuropsychological performance, and functional magnetic resonance imaging (fMRI) during a
working memory task. Fasting blood glucose levels and hemoglobin A1C measurements were
obtained via a blood draw on study day 1 for the CHAMP study and on the pre-study day visit
for the DIET study. Both measurements were obtained before any study specific manipulations
occurred. Systolic and diastolic blood pressure, height, and weight were also taken on those days.
Body mass index (BMI) was calculated. The psychiatric and neuropsychological measures used
in this study are described below.
Psychiatric Evaluations
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The Brief Cognitive Rating Scale (BCRS; Reisberg & Ferris, 1988) was used to assess
functional and cognitive abilities in 5 different areas. These include concentration, recent
memory, past memory, orientation, and functioning and self-care. It is commonly used in
conjunction with the Global Deterioration Scale (GDS; Reisberg et al., 1982) that assessed the
severity of cognitive impairment in patients. The Mattis Dementia Rating Scale (MDRS; Mattis,
1988) was used to assess the overall level of cognitive functioning. The MDRS measured
performance in the domains of attention, initiation and perseveration, construction,
conceptualization, and memory to assess cognitive changes associated with dementia. The Beck
Depression Inventory (BDI; Beck et al., 1996) is a 21-item self-report instrument that was used
to determine severity of depression in the participants. The Beck Anxiety Inventory (BAI; Steer
et al., 1997) is a 21-item self-report instrument that was used to determine the presence and
severity of anxiety symptoms in the participants. The Test of Premorbid Functioning (TOPF;
Wechsler, 2011) was used to estimate pre-morbid memory and cognition. The Structured
Clinical Interview for DSM-IV (SCID; First et al., 2015) is a diagnostic exam that was used to
screen for Axis 1 psychiatric disorders in the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV).
In order to exclude individuals with significant cognitive or behavioral impairments.
Participants were required to have a MDRS score of greater than 123 and an estimated IQ of
above 80. Participants were also excluded on the basis of having an untreated or unremitted
psychiatric disorder as determined by the SCID, the BDI, and the BAI.
Neuropsychological Measures
The Cognitive Change Index (CCI; Saykin et al., 2006) self-questionnaire was used to
measure self-perception of cognitive decline in the areas of memory, executive functioning, and
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language domains. It is moderately related to objective test performance in those areas. The
Symbol Digit Modalities Test (SDMT; Forn et al., 2013) was used to measure attention and
processing speed. In the SDMT, participants were asked to complete a 90 second substitution
task in which they had to pair numbers with geometric figures using a reference key. The Letter
Number Sequencing (LNS; Wechsler, 2008) is a subtest on the Wechsler Adult Intelligence
Scale used to measure verbal working memory. In the LNS, participants were asked to sequence
a random order of numbers and letters. The Repeatable Battery for the Assessment of
Neuropsychological Status (RBANS; Randolph et al., 1998) is an individually administered
battery that was used to measure cognitive decline or improvement across different cognitive
domains. These cognitive domains included immediate memory, visuospatial/constructional,
language, attention, delayed memory, and executive functioning tests. The Delis-Kaplan
Executive Function System (D-KEFS; Delis et al., 2001) is a neuropsychological test that
measured verbal and nonverbal executive functioning. It is composed of 9 subtests, however
only the trail making test and the verbal fluency test were used in this study. The Trail Making
Test is a visual-motor sequencing task that was used to measure cognitive flexibility and the
Verbal Fluency Test was used to measure letter fluency, category switching, and category
fluency.
fMRI N-back Task
The n-back task is a widely used, reliable measure of working memory performance. It
reliable activates bilateral frontal, parietal, and cerebellar working memory networks (Meule,
2017). The n-back task involved participants attending to a series of stimuli and responding
whenever a stimulus is presented that is the same as the one presented n trials before.
Participants were shown a series of consonant letters (except L, W, and Y), one for every three
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seconds. There were four different conditions that were presented to the participants: 0-back, 1back, 2-back, and 3-back. In each of the conditions, participants decided whether the currently
presented letter matched the letter that was presented n-trials back in the sequence. If the
participant believed that it matched, they pressed a match button; if they did not believe that it
matched, they pressed a mismatch button. Participants were given two practice rounds of each of
the four different conditions on a computer before completing the n-back task in the MRI
scanner. The accuracy and reaction times were recorded for each of the trials (Meule, 2017).
fMRI Data Acquisition and Processing
fMRI data was obtained after the first week of controlled diet in the DIET study and on
study day 1 in the CHAMP study. The Philips 3T Achieva d-Stream MRI scanner used in this
study was located at the UVM MRI Center for Biomedical imaging at the University of Vermont
Medical Center. The MRI imaging protocol used was developed for the multicenter NIH-funded
Adolescent Brain Cognitive Development (ABCD) study and includes simultaneous multi-slice
imaging, called MultiBand SENSE. MultiBand SENSE acquisition schemes allow the
acquisition from more than one spatial coordinate at a time and thus can accelerate functional
MRI acquisitions (Setsompop et al., 2012). The structural MRI acquisition was comprised of T1
and T2 weighted images that had an isotropic resolution of 0.8mm and a T2-FLAIR isotropic
resolution of 1.0mm. The task and resting state fMRI parameters were TR 800ms, TE 35ms, flip
angle 52 degrees, 2.4mm isotropic imaging resolution with a 216×216×144mm3 field of view
using a multiband acceleration factor of 6 (60 slices, no gap). MRI images reviewed by a
neuroradiologist in order to exclude intracranial pathology.
fMRI was performed using EpiBOLD (echoplanar blood oxygenation level dependent)
imaging using a single-shot sequence (TR 800 ms, TE 35 ms, flip angle 90 degrees, 1 NSA for
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615 volumes). Resolution was 1.8 mm x 1.8 mm x 1.8 mm. Sixty contiguous slices 1.8 mm thick
with no gap were obtained in the axial oblique plane parallel to the AC-PC plane using a FOV of
240 mm and a matrix size of 80 × 80. Field map correction for magnetic inhomogeneities was
accomplished by acquiring images with offset TE at the end of the functional series (Dumas et
al., 2018).

fMRI Analyses
Structural and fMRI preprocessing used standard procedures implemented in the Dumas
Lab similar to prior published fMRI work (Dumas et al., 2010; Dumas et al., 2012; Dumas et al.
2019). These included realignment of volumes to the first volume to minimize the effects of head
movements, as well as spatial and temporal filters to remove aliased signal correlated to
background respiration and heart rate. The anatomical and functional images were also coregistered and normalized to Talairach space. We performed a multisubject analysis in Brain
Voyager QX. We used multiple linear regression of the signal time course at each voxel to
estimate the hemodynamic response. We chose to focus our image-based analysis on the 2-back
minus 0-back contrast. Given the small sample available for the imaging analysis, we did not
compute any corrections for multiple comparisons.
Statistical Analyses
The primary goal of this study was to examine the relationship between pre-clinical
insulin resistance, as estimated by fasting blood glucose levels, and performance on a variety of
cognitive measures using Pearson’s correlations in SPSS. Next, participants were divided into a
high fasting blood glucose group (fasting blood glucose level ≥ to 100 mg/dL; clinically
categorized as prediabetes) and a low fasting blood glucose group (fasting blood glucose level <
100 mg/dL). Independent samples t-tests were performed to assess whether participants in the
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high fasting blood glucose group performed differently from the low fasting blood glucose
group. Additional correlational analyses were performed in order to evaluate whether secondary
factors, including sex, BMI, A1C levels, diastolic and systolic blood pressure, and level of
education, were associated with performance on each cognitive test. To examine the
relationships between fasting blood glucose and BOLD signal from clusters activated in the
working memory task, we performed a Pearson’s correlation. We also performed a Pearson’s
correlation between BMI and BOLD signal from the activated clusters from the n-back task.
Results
Cognitive Test Performance
We found that higher fasting blood glucose levels were positively correlated with BCRS
(r= 0.64, p= 0.001) and GDS scores (r= 0.64, p= 0.001). Fasting blood glucose levels were not
correlated with performance on the other cognitive measures. The independent samples t-test
using high and low glucose groups found that there were differences between the
Initiation/Perseveration domain of the MDRS for the high glucose (M= 11.20, SD= 0.42) and
low glucose (M= 10.29, SD= 1.25) groups; t(15)= 2.16, p= 0.047. There was also a difference in
the language domain of the RBANS scores for the high glucose (M=104.23, SD= 8.16) and low
glucose (M= 97.60, SD= 5.89) groups; t(20)= 2.15, p= 0.044.
Additional correlational analyses found that BMI was negatively correlated with
performance on the RBANS (see Figures 1-3). Specifically, BMI was negatively correlated with
RBANS total score (r= -0.61, p= 0.003), RBANS delayed memory (r= -0.63, p= 0.002), and
RBANS attention (r=-0.59, p= 0.005). Sex, age, A1C, level of education, diastolic blood
pressure, and systolic blood pressure were not correlated with performance on any of the
cognitive measures.
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fMRI Activation Data
We examined working-memory related brain activation in the n-back task in seven of the
participants for whom we had imaging data. When we compared the 2-back working memory
load condition to the 0-back condition, we found the expected bilateral frontal, parietal, and
cerebellar working memory network to be activated (Cohen, 1997). To test our hypothesis that
higher levels of fasting blood glucose influenced brain functioning during a working memory
task, we performed a Pearson’s correlation between fasting blood glucose levels and BOLD
signal from clusters activated during the N-back task in the expected working memory regions.
We found that fasting blood glucose levels were correlated with activation in the right angular
gyrus in the parietal lobe (Brodmann area 39) during the 0-back condition (r= 0.85, p= 0.016)
and the 2-back condition (r= 0.78, p= 0.037) (See Table 2). We also found that BMI was
correlated with activation in the left premotor and supplemental motor area (Brodmann area 6)
during the 1-back condition (r= 0.85, p= 0.015) (see Table 2).
Discussion
There is a growing literature examining the effects of Type 2 diabetes, insulin resistance,
and impaired glucose tolerance on cognition in older adults. We contribute to this literature by
examining the impact of fasting blood sugar on cognitive function in older adults whose fasting
blood glucose levels were not yet clinically elevated. Our first hypothesis was that fasting blood
glucose levels at the higher end of the normal range would be negatively correlated with
cognitive performance, particularly on measures of early cognitive processing stages. Results of
our correlational analyses showed that higher fasting blood glucose levels were positively
associated with BCRS and GDS scores, which are both clinician ratings of cognitive functioning.
The BCRS and GDS are used to stage a person who is showing signs of a dementia such as
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Alzheimer’s disease, with higher scores indicating more adverse changes in cognition (Reisberg
& Ferris, 1988; Reisberg et al., 1982). Importantly, these measures are sensitive to a person’s
subjective complaints of cognitive decline. Subjective cognitive decline refers to when a person
feels that they are cognitively impaired but do not yet show objective deficits in cognitive test
performance. The presence of subjective cognitive complaints is thought to be an early clinical
marker of dementia as it has been shown to precede objective cognitive deficits (Parfenov et al.,
2020). Thus, our findings suggest that elevated fasting blood glucose measures may be affecting
the early stages of cognitive decline in which a person experiences a subjective deficit in
cognition before any objective changes in performance are observed. However, it is worth noting
that we did not find the expected correlation between fasting blood glucose and performance on
the CCI, which is a subject-reported measure of subjective cognitive decline. There was also
little variance in BCRS and GDS scores due to our small sample size, indicating the need for
future studies to ensure the validity of our results.
Fasting blood glucose was not correlated with performance on any of our other cognitive
measures. In particular, we did not find reductions in global cognition, as measured by the
RBANS total and MDRS total. Global cognition refers to the overall level of cognitive
functioning of an individual. Our results stand in contrast to prior research that had found that
increases in insulin resistance were associated with reductions in global cognition in cognitively
normal adults (Laws et al., 2017; Kong et al., 2018). One way to interpret these results is that the
cognitive profile of pre-clinical insulin resistance as estimated by elevated blood glucose levels
was seen in domain-specific cognitive impairments rather than in measures of global cognition.
These findings are supported by other studies that found that insulin resistance mainly affects the
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attention, executive function, and processing speed, which may not be accurately assessed using
only measures of global cognition (Yeung et al., 2009).
The results of the independent samples t-test showed that there were significant
differences in performance between participants in the high fasting blood glucose (blood glucose
level ≥ to 100 mg/dL; clinically categorized as prediabetes) and low blood glucose groups (blood
glucose level < 100 mg/dL) on the Initiation/Perseveration (I/P) domain of the MDRS. The I/P
domain of the MDRS is a composite measure of several executive skills (Mattis, 1988). Given
that insulin resistance has been shown to affect executive functioning, it is likely that executive
function is also affected in the pre-clinical stages of insulin resistance (Schuur et al., 2010;
Abbatecola et al., 2004). Thus, the results of our study supported that those effects on executive
functioning may even be seen in patients who are not yet clinically impaired. However, it is
worth noting that we did not find significant group differences in performance on the DKEFS,
which is another measure of executive function. Furthermore, the results of our correlational
analyses did not show significant correlations between fasting blood glucose and measures of
executive functioning.
There was also a difference in performance on the language domain of the RBANS
between the high glucose and low glucose groups. The language domain of the RBANS is
primarily a measure of verbal fluency, which includes phonetic and semantic fluency. Verbal
fluency is commonly thought of as being another measure of executive function. Insulin
resistance has been associated with poorer verbal fluency in multiple studies: One study found
that insulin resistance predicted poorer verbal fluency and a steeper decline in verbal fluency
(Eklbad et al., 2017), whereas another found that insulin resistance was associated with poorer
verbal fluency in women in particular (Ekblad, 2015). Interestingly, verbal fluency is also
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commonly affected in Alzheimer’s dementia (Weakley, 2014). However, our findings suggest
the opposite pattern as it was the high fasting blood glucose group who had better verbal fluency
performance compared to the low fasting blood glucose group. We did not see these significant
group differences on any of the verbal fluency measures of the DKEFS. Correlational analyses
also did not show a relationship between measures of verbal fluency and fasting blood glucose
levels. Given these discrepancies, more research is needed to observe if this pattern between
fasting blood glucose and verbal fluency remains true in large sample sizes.
In addition to examining performance on a variety of cognitive tests, we also looked at
brain activation during an fMRI working memory task. Our hypothesis was that higher fasting
blood glucose levels would be correlated with compensatory changes in brain activation during
the n-back task. As expected, we found the bilateral frontal, parietal, and cerebellar working
memory network to be activated during the n-back task (Cohen, 1997). We also found that
fasting blood glucose levels were correlated with increased activation in the right angular gyrus
in the parietal lobe during the 0-back condition and the 2-back condition. The angular gyrus
plays a key role in verbal working memory and is activated during the retrieval of verbal
information (Seghier, 2013). One way to interpret these findings is that greater brain activation in
the 2-back condition, as estimated by increases in the fMRI BOLD signal, was associated with
decreased neural efficiency during the retrieval part of the working memory task. This view is
consistent with prior neuroimaging studies that have shown that increased brain activation in
working memory regions is associated with less efficient thinking patterns (Neubauer & Fink,
2009).
It is also interesting to note that the angular gyrus is part of the default mode network,
which has recently been implicated as playing a role in working memory processes (Piccoli et
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al., 2015; Koshino et al., 2014). Additionally, hyperglycemia has been associated with impaired
deactivation of the default mode network (Marder et al., 2014). Thus, it is possible that
hyperglycemia may contribute to brain abnormalities particularly affecting the default mode
network. Although task-related activation in the right angular gyrus was associated with fasting
blood glucose in our study, our results can only be interpreted in a preliminary manner because
we were unable to correct for multiple comparisons in the small number of participants for
whom we had imaging data for at this time. Correcting for multiple comparisons is important in
order to minimize false positives and identify areas of brain activity that reflect true effects (Han
& Glenn, 2018). Thus, further studies with larger sample sizes that correct for multiple
comparisons are needed to verify if there are any changes in brain activation associated with
elevated fasting blood glucose levels during a working memory task.
Secondary analyses showed that that BMI was negatively correlated with performance on
the RBANS total, as well as with performance on the RBANS attention RBANS delayed
memory. These findings support the idea that obesity is an additional risk factor for cognitive
dysfunction. In fact, studies that have found that BMI is correlated with the development of
Alzheimer’s disease and other dementias, particularly in subjects with insulin resistance (BenitoLeon et al., 2013). We also found that BMI was correlated with activation in the left premotor
and supplemental motor area during the 1-back condition of the n-back task. This finding
indicates that BMI may also be associated with less efficient thinking patterns during a working
memory task. Due to the complex interactions between the many factors associated with
metabolic syndrome, it is difficult to make definitive conclusions about their temporal
relationships. Thus, our results show that obesity may be an additional factor mediating the
relationship between insulin resistance, hyperglycemia, and cognitive dysfunction.
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Limitations
There are several limitations of this study to consider. One major limitation of this study
is its small sample size (n=22). Because the expected association between high-normal fasting
blood glucose and cognitive performance is relatively small compared to the association between
clinically elevated fasting blood glucose and cognitive performance, our study may not have had
the statistical power to expose such a small effect. Thus, future studies with larger sample sizes
are needed to confirm that the results of our study are not due to chance.
Another limitation of this study was that we used fasting blood glucose levels to estimate
the degree of insulin resistance in the participants. While elevated fasting blood glucose is a
strong indicator of insulin resistance, it is not a direct measurement of insulin resistance. In other
words, it is important to keep in mind that plasma glucose levels and insulin resistance are
related but not equivalent concepts. There are factors in addition to insulin resistance, such as
decreased insulin secretion, age, and triglycerides that may have affected the fasting blood
glucose levels of the participants (Nishi et al., 2005; Aoyama-Sasabe et al., 2014). Thus, future
studies that are able to utilize more accurate assessments of insulin resistance are needed to
confirm our findings. Possible indexes for insulin resistance include the Homeostasis Model
Assessment (HOMA) and the Quantitative Insulin Sensitivity Check Index (QUICKI), which
both take into account fasting insulin and fasting glucose levels to estimate the degree of insulin
resistance (Muniyappa & Madan, 2018).
Lastly, the outcomes of this study indicate a relationship between elevated fasting blood
glucose and cognitive performance in specific areas, but we cannot demonstrate cause and effect
due to the cross-sectional nature of our study. While there are studies that support the idea that
hyperglycemia and insulin resistance precipitate the symptoms of cognitive dysfunction, we
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cannot exclude the possibility that the early CNS defects associated with cognitive dysfunction
are what give rise to metabolic dysfunction. In addition to this possibility, it is likely that there
are additional factors mediating the relationship between insulin resistance and cognitive
dysfunction. Our study addressed the effects of aging and obesity on both insulin resistance and
cognition. Other factors that were not addressed but that fall under the category of metabolic
syndrome risk-factors include hypertension, dyslipidemia, abdominal obesity, and impaired
cerebral vasculature (Panza et al., 2010).
Conclusions
In summary, the results of this study indicate that fasting blood glucose levels at the higher
end of the normal range may still negatively impact cognition in older adults, particularly seen in
measures of subjective cognitive functioning and executive functioning. Preliminary fMRI
imaging data also indicates the need for future research examining if there are any changes in
brain activation associated with elevated fasting blood glucose levels during memory tasks, as
this may be indicative of decreased neural efficiency in this population. Future studies with
larger sample sizes are needed to better understand the relationship between impaired glucose
tolerance, insulin signaling, and cognitive dysfunction in older adults. Given that dementia and
Type 2 diabetes are both characterized by long prodromal periods, it is particularly important to
identify and address risk factors early to prevent disease progression. The outcome of this study
and additional studies may help to inform new blood glucose control guidelines in healthcare, as
even the higher end of the normal blood glucose range may be associated with cognitive decline.
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Table 1. Demographic data and fasting blood glucose levels, BMI, A1C, systolic and
diastolic blood pressure (means and standard deviations) for all study participants (n=22).
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Table 2. Brain activation clusters correlated with fasting blood glucose and BMI, respectively,
during the 2-back minus 0-back condition of the n-back task. Includes Talairach coordinates,
region descriptions (Brodmann’s area, BA), t values, and p values.
Contrast

Coordinates

Region

(x,y,z)

Description

t-value

p-value

7.11

<0.001

6.30

<0.001

2-back minus
0-back
Right
(Correlated
40, -53, 39

angular gyrus

with fasting
(BA 39)
blood glucose
levels)
2-back minus

Left premotor

0-back

/supplemental
-25, 5, 53

(Correlated

motor area

with BMI)

(BA 6)

41

GLUCOSE AND COGNITIVE DYSFUNCTION
Figure Legends
Figure 1. Relationship between BMI and scores on the RBANS total scaled (r=-0.610, p=0.003).
Figure 2. Relationship between BMI and scores on the RBANS attention (r=-0.585, p=0.005).
Figure 3. Relationship between BMI and scores on the RBANS delayed memory
(r= -0.634, p=0.002).
Figure 4. Activation map for the n-back task comparing the 2-back minus the 0-back in the left
premotor and supplemental motor area (Brodmann Area 6). Red colors represent increasing
activation for the 2-back compared to the 0-back condition and blue colors represent decreasing
activation for the 2-back compared to the 0-back condition.
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Figure 2.
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Figure 3.
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Figure 4.

46

